首页> 外文期刊>Japanese Journal of Pharmacology >Use of Anti-Platelet-Endothelial Cell Adhesion Molecule-1 Antibody in the Control of Disease Progression in Established Collagen-Induced Arthritis in DBA/1J Mice
【24h】

Use of Anti-Platelet-Endothelial Cell Adhesion Molecule-1 Antibody in the Control of Disease Progression in Established Collagen-Induced Arthritis in DBA/1J Mice

机译:抗血小板-内皮细胞粘附分子-1抗体在已建立的胶原诱导的DBA / 1J小鼠疾病控制中的应用。

获取原文
           

摘要

References(41) Cited-By(9) Platelet-endothelial cell adhesion molecule-1 (PECAM-1) is expressed on the membrane of leukocytes and vascular endothelial cells. PECAM-1 has been shown to play an important role in the process of leukocyte transmigration in various animal models of acute inflammation. We investigated the role of PECAM-1 in the progression of arthritis by systemically administering anti-murine PECAM-1 monoclonal antibody, 2H8, to DBA/1J mice with collagen-induced arthritis (CIA). Subcutaneous administration of dexamethasone (0.5 mg/kg per 2 days) significantly reduced hindpaw swelling and the clinical score of established CIA. Intraperitoneal administration of 2H8 (0.25 mg/mouse per 2 days) significantly inhibited hindpaw swelling in a time-dependent manner. 2H8 also significantly prevented further deterioration in the clinical score, but failed to reverse joint destruction discernible at the histological level. Both dexamethasone and 2H8 inhibited body weight decrease by preventing the further development of arthritis. Histopathological assessment revealed that 2H8, as well as dexamethasone, inhibited inflammatory cell transmigration into the synovium of the hind paw joint and ameliorated synovitis and cartilage erosion. These results suggest that PECAM-1 plays an important role in the progression of CIA and that an inhibitor of PECAM-1 might have therapeutic value for clinical treatment of rheumatoid arthritis.
机译:参考文献(41)被引用的By(9)血小板内皮细胞粘附分子1(PECAM-1)在白细胞和血管内皮细胞的膜上表达。在各种急性炎症动物模型中,PECAM-1已显示在白细胞迁移过程中起重要作用。我们通过向具有胶原蛋白诱导的关节炎(CIA)的DBA / 1J小鼠全身性施用抗鼠PECAM-1单克隆抗体2H8,研究了PECAM-1在关节炎进展中的作用。地塞米松的皮下给药(每2天0.5 mg / kg)可显着降低后爪肿胀和已建立的CIA的临床评分。腹膜内施用2H8(每2天0.25 mg /小鼠)以时间依赖性方式显着抑制后爪肿胀。 2H8还显着防止了临床评分的进一步恶化,但未能逆转组织学水平上可见的关节破坏。地塞米松和2H8均通过防止关节炎的进一步发展而抑制了体重下降。组织病理学评估显示,2H8和地塞米松抑制炎症细胞向后爪关节滑膜的迁移,并减轻滑膜炎和软骨侵蚀。这些结果表明,PECAM-1在CIA的进展中起重要作用,并且PECAM-1的抑制剂对于类风湿性关节炎的临床治疗可能具有治疗价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号